Table 1.
The Baseline Demographic and Clinical Characteristics of Patients with Metastatic Castration-Resistant Prostate Cancer
| Variable | Overall (n = 37) |
CTC Positive (n = 20) |
CTC Negative (n = 17) |
P Value |
|---|---|---|---|---|
| Age, median, IQR, years | 72(67-79) | 73(64-78) | 72(68-80) | .437 |
| Race (%) | ||||
| Caucasian | 35 (94.6) | 18 (90.0) | 17 (100.0) | .407 |
| African American | 1 (2.7) | 1 (5.0) | 0 (0.0) | |
| Hispanic | 1 (2.7) | 1 (5.0) | 0 (0.0) | |
| PSA, median, IQR, ng/ml | 20.9 (11.6-96.8) | 65.8(17.4-359.3) | 14.4 (7.8-25.8) | .011 |
| No. of prior therapy (%) | ||||
| 0 | 17 (45.9) | 7 (35.0) | 10 (58.8) | .259 |
| 1 | 15 (40.5) | 9 (45.0) | 6 (35.3) | |
| 2 | 5 (13.5) | 4 (20.0) | 1 (5.9) | |
| Gleason score (%) | ||||
| ≤7 | 16 (43.2) | 8 (40) | 8 (47.0) | .803 |
| 8 | 3 (8.1) | 2 (10) | 1 (5.9) | |
| ≥9 | 17 (46.0) | 10 (50) | 7 (41.2) | |
| Unknown | 1 (2.7) | 0 (0.0) | 1 (5.9) | |
| ECOG (%) | ||||
| 0 | 21 (56.8) | 8 (40.0) | 13 (76.5) | .079 |
| 1 | 13 (35.1) | 10 (50.0) | 3 (17.6) | |
| 2 | 3 (8.1) | 2 (10) | 1 (5.9) | |
| Opioid analgesic (%) | ||||
| Yes | 26 (70.3) | 10 (50) | 16 (94.1) | .003 |
| No | 11 (29.7) | 10 (50) | 1 (5.9) | |
| Albumin, median, IQR, g/dl | 4.1(3.9-4.3) | 4.1(3.8-4.3) | 4.2(4.0-4.4) | .502 |
| Hemoglobin, median, IQR, g/dl | 12.8(11.7-13.9) | 12.6(10.6-13.2) | 12.8(12.5-14.6) | .825 |
| Alkaline phosphatase, Median, IQR, g/dl | 102.0(80.5-170.5) | 117.0(80.3-267.5) | 102.0(82.5-123.5) | ≪.001 |
| CTC probability | 0.95 (0.06-0.99) | 0.99(0.98-0.99) | 0.056(0.006-0.170) | ≪.001 |
| Extent of disease at baseline | ||||
| Bone metastasis | ||||
| Yes | 33 (89.2) | 19 (95.0) | 14 (82.4) | .217 |
| No | 4 (10.8) | 1 (5.0) | 3 (17.6) | |
| Nodal metastasis | ||||
| Yes | 24 (64.9) | 16 (80.0) | 8 (47.1) | .036 |
| No | 13 (35.1) | 4 (20.0) | 9 (52.9) | |
| Visceral metastasis (liver and/or lung) |
||||
| Yes | 10 (27.0) | 6 (30.0) | 4 (23.5) | .659 |
| No | 27 (73.0) | 14 (70.0) | 13 (76.5) |
P value: CTC+ vs. CTC−. ECOG, Eastern Cooperative Group.